“Does Medicare cover GLP-1s” has three different answers in 2026, and which one applies to you is decided by why the drug was prescribed, not by whether you have good coverage. The same beneficiary, on the same drug, can pay $50, roughly $175 a month, or $349, depending entirely on the diagnosis on the prescription.
Everything below comes from CMS and Medicare.gov’s own pages plus KFF’s analysis of the demonstration, checked September 4, 2026. Manufacturer prices come from Novo Nordisk’s NovoCare Pharmacy pages the same day.
What Does a GLP-1 Actually Cost on Medicare?
| Your situation | Low | Average | High |
|---|---|---|---|
| Eligible for the Medicare GLP-1 Bridge (weight loss) | $50/mo | $50/mo | $50/mo |
| Covered by your Part D plan (diabetes, cardiovascular risk, sleep apnea, MASH) | $0/mo after you hit the cap | about $175/mo averaged over the year | $2,100 total for 2026, plus deductible timing |
| Not covered, buying direct from the manufacturer | $149/mo (Wegovy or Ozempic tablets, starting dose) | $299/mo | $499/mo (Ozempic 2 mg pen) |
| Not covered, paying retail with no program | - | - | four figures a month |
The middle row is the one people misread. The $2,100 figure in 2026 is an annual cap on everything your Part D plan covers, not a per-drug charge, and once you hit it you pay $0 for covered Part D drugs for the rest of the calendar year. KFF notes the cap rises to $2,400 in 2027.
The Part D Weight-Loss Exclusion, and the Way Around It
Medicare has been barred by statute since the start of Part D from covering drugs when they are used specifically for weight loss. KFF puts it plainly: people on Medicare can get GLP-1s covered by a Part D plan only when they are used for a medically accepted FDA-approved indication other than obesity.
That is the whole game. The workaround is not a loophole, it is the actual rule: if your GLP-1 is prescribed for type 2 diabetes, cardiovascular risk reduction, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH, your Part D plan covers it under normal formulary rules. If it is prescribed only to lose weight and keep it off, Part D cannot pay, and CMS built a separate demonstration to fill that gap.
What you pay when Part D does cover it
Medicare.gov publishes the 2026 parameters. No Part D plan may charge a deductible above $615. In the initial coverage stage you pay 25% coinsurance on generics and brand drugs. Once your out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026, catastrophic coverage kicks in and you pay nothing for covered drugs for the rest of the year.
For a four-figure-a-month drug like a branded GLP-1, that math is fast. A beneficiary at 25% coinsurance on a drug in that price range typically burns through the $2,100 cap partway through the year, which makes the realistic 2026 ceiling for a covered GLP-1 about $2,100 in total, or roughly $175 a month averaged across twelve months. Your plan’s negotiated price sets how quickly you get there, so check your own plan’s drug list before you assume.
One more timing note worth knowing: KFF reports that semaglutide was selected for Medicare drug price negotiation in 2025, with a negotiated price taking effect in 2027.
Does Medicare Cover Ozempic?
Yes, for type 2 diabetes and other medically accepted indications, through your Part D plan and your plan’s normal cost sharing. Ozempic is a diabetes drug by label, which is exactly the situation Part D was built to pay for.
What Ozempic does not have is a $50 route. CMS’s eligible-drug list for the GLP-1 Bridge contains three products, and Ozempic is not one of them. If your plan denies it, or you have no Part D coverage, the fallback is Novo Nordisk’s self-pay channel: $199 a month introductory pricing on the 0.25 mg and 0.5 mg pens for two fills through December 31, 2026, then $349 a month for 0.25 mg through 1 mg and $499 a month for the 2 mg pen. The Ozempic pill runs $149, $199, or $299 a month depending on strength. Our Ozempic cost without insurance guide covers the full ladder.
Does Medicare Cover Wegovy?
Wegovy is the one drug that can go either way, and the difference is worth real money.
Prescribed to reduce the risk of major cardiovascular events in someone with known heart disease, Wegovy is a Part D covered drug, and CMS is explicit that a prescription written for MACE risk reduction should be routed to the Part D plan even if the patient also wants to lose weight.
Prescribed purely for weight management, Part D cannot cover it, but Wegovy is on the Bridge list in both forms, injection and tablets. An eligible beneficiary pays $50 a month. If neither door opens, NovoCare’s self-pay price is $199 a month introductory for two fills through December 31, 2026, then $349 a month for the standard pens and $399 for Wegovy HD 7.2 mg, or $149 to $299 a month for the tablets. See Wegovy cost without insurance and oral Wegovy cost for the dose-level detail.
The Medicare GLP-1 Bridge: $50 a Month, With Real Catches
CMS launched the Medicare GLP-1 Bridge on July 1, 2026 and it runs through December 31, 2027. It is a Section 402 demonstration that sits outside the Part D benefit entirely, which is what makes both the price and the catches unusual.
What it covers. Exactly three products, per CMS: Foundayo, Wegovy (injection and tablets), and the Zepbound KwikPen. Zepbound single-dose vials and single-dose pens are excluded, and Mounjaro is not on the list. If you are on a Zepbound vial today, see Zepbound vials cost and Zepbound KwikPen cost, because the device you are prescribed decides whether you get the $50 price.
Who qualifies. You must be 18 or older, enrolled in an eligible Part D plan type, prescribed the drug to reduce excess body weight alongside diet and exercise, and meet one of three clinical thresholds at the time you started GLP-1 therapy: BMI of 35 or higher; BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above; or BMI of 27 or higher with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
The counterintuitive part. A type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH diagnosis makes you ineligible for the $50 Bridge price. CMS states that because those indications are already Part D coverable, beneficiaries who have them must obtain GLP-1s through their Part D plan and cannot use the Bridge even if they otherwise meet the clinical criteria. Being sicker, in this one narrow sense, moves you to the more expensive door.
What the $50 does not do. CMS and Medicare.gov both spell this out. The Part D deductible does not apply, none of the $50 counts toward your TrOOP or the $2,100 out-of-pocket limit, Extra Help and the low-income subsidy cannot lower it, the Medicare Prescription Payment Plan cannot spread it across months, and it will not appear on your Part D Explanation of Benefits or Medicare Summary Notice.
How you get it. Your prescriber sends the prescription to the pharmacy, the pharmacy submits the claim to the Bridge and requests prior authorization, and the prescriber returns the attestation form, typically within 24 to 72 hours. Approval or denial is mailed to you and sent to your prescriber within 72 hours of submission. There is no appeals process. Once approved, your prior authorization is valid through December 31, 2027, including refills and dose changes, unless you switch to a different GLP-1.
Behind the scenes, KFF reports that manufacturers agreed to supply the Bridge drugs at a $245 monthly net price, with CMS reimbursing pharmacies at no lower than wholesale acquisition cost less your copay.
Part B vs. Part D: Which One Pays
Part B covers drugs you would not normally give to yourself, mostly things administered in a doctor’s office or hospital outpatient setting, at 20% coinsurance after the Part B deductible. GLP-1s are self-administered pens, vials, and tablets, so they fall under Part D, not Part B. If you have Original Medicare with no Part D plan, you have no drug coverage for a GLP-1 at all, and you also cannot use the GLP-1 Bridge, because Part D enrollment is a requirement.
That matters for a specific group: people who skipped Part D because they took few medications. Medicare.gov notes that discount cards, including TrumpRx, are not creditable coverage, so using them does not protect you from the Part D late enrollment penalty, which is 1% of the $38.99 national base beneficiary premium for every uncovered month, added to your premium permanently.
How to Pay Less
1. Ask which door your prescription is going through. The single most valuable question you can ask your prescriber is whether the prescription is being written for weight management (Bridge, $50) or for a Part D covered indication (your plan). It changes your bill by hundreds of dollars a month.
2. Check Bridge eligibility before assuming you do not qualify. Medicare.gov has an eligibility questionnaire on its weight loss drugs page, and 1-800-MEDICARE can check the status of a prior authorization. Eligibility is judged on your BMI when you started therapy, not today’s BMI, which helps people who have already lost weight.
3. If you are excluded from the Bridge, price the manufacturer’s self-pay channel. Medicare beneficiaries are shut out of commercial savings cards, but both Novo Nordisk and Eli Lilly will sell to you as a self-pay patient outside your insurance. Our cheapest GLP-1 guide compares every current program.
4. Compare your plan’s price against the cash price every year at open enrollment. Plans change formularies and negotiated prices annually. If your plan covers the drug but your coinsurance is worse than $299 a month, self-pay is the cheaper route, with the caveat that self-pay dollars do not count toward your deductible or the $2,100 cap.
5. Use the Medicare Prescription Payment Plan for the covered route. It does not lower your cost, but it spreads your Part D out-of-pocket costs across the calendar year, which matters when a GLP-1 front-loads your spending into January and February.
6. Ask about patient assistance if you are on a fixed income. Manufacturer assistance programs are separate from savings cards and do not always exclude Medicare beneficiaries. Our guide to negotiating medical bills covers how to work the appeals and assistance path when a claim is denied.
The Bottom Line
Medicare does cover GLP-1s in 2026, but through two separate systems with opposite eligibility rules. If you want one for weight loss and you meet the BMI criteria without a diabetes, sleep apnea, or MASH diagnosis, the Medicare GLP-1 Bridge puts you at $50 a month on Foundayo, Wegovy, or the Zepbound KwikPen through December 31, 2027. If you have one of those diagnoses, your Part D plan covers the drug instead and your 2026 ceiling is $2,100 out of pocket for all covered drugs. If you fall through both, you are a cash patient at $149 to $499 a month, which is the same market covered in GLP-1 pills cost and GLP-1 cost without insurance.